Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Autoimmunity in visual loss.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
RTL therapy for multiple sclerosis: a Phase I clinical study.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Society for Neuroscience Annual Meeting
Multiple sclerosis: A lifestyle disease?
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Interferon in relapsing-remitting multiple sclerosis.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Pages
« first
‹ previous
…
100
101
102
103
104
105
106
107
108
…
next ›
last »